These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 21087066

  • 1. Lipid lowering for secondary prevention of cardiovascular disease in older adults.
    Thomas JE, Tershakovec AM, Jones-Burton C, Sayeed RA, Foody JM.
    Drugs Aging; 2010 Dec 01; 27(12):959-72. PubMed ID: 21087066
    [Abstract] [Full Text] [Related]

  • 2. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Dec 01; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 3. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
    Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.
    Drugs; 2013 Jul 01; 73(10):1025-54. PubMed ID: 23754124
    [Abstract] [Full Text] [Related]

  • 4. Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Ponce OJ, Larrea-Mantilla L, Hemmingsen B, Serrano V, Rodriguez-Gutierrez R, Spencer-Bonilla G, Alvarez-Villalobos N, Benkhadra K, Haddad A, Gionfriddo MR, Prokop LJ, Brito JP, Murad MH.
    J Clin Endocrinol Metab; 2019 May 01; 104(5):1585-1594. PubMed ID: 30903687
    [Abstract] [Full Text] [Related]

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct 01; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 6. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S.
    Eur Heart J; 2018 Apr 07; 39(14):1172-1180. PubMed ID: 29069377
    [Abstract] [Full Text] [Related]

  • 7. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM.
    Ann Pharmacother; 2002 May 07; 36(5):751-7. PubMed ID: 11978147
    [Abstract] [Full Text] [Related]

  • 8. Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.
    Dugré N, Lindblad AJ, Perry D, Allan GM, Braschi É, Falk J, Froentjes L, Garrison SR, Kirkwood JEM, Korownyk CS, McCormack JP, Moe SS, Paige A, Potter J, Thomas BS, Ton J, Young J, Weresch J, Kolber MR.
    Can Fam Physician; 2023 Oct 07; 69(10):701-711. PubMed ID: 37833094
    [Abstract] [Full Text] [Related]

  • 9. Lipid-lowering agents for nephrotic syndrome.
    Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L.
    Cochrane Database Syst Rev; 2013 Dec 10; (12):CD005425. PubMed ID: 24327265
    [Abstract] [Full Text] [Related]

  • 10. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
    Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD.
    Drug Saf; 2010 Mar 01; 33(3):171-87. PubMed ID: 20158283
    [Abstract] [Full Text] [Related]

  • 11. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT.
    Circulation; 2019 Jun 18; 139(25):e1144-e1161. PubMed ID: 30586775
    [Abstract] [Full Text] [Related]

  • 12. Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.
    Jacobson TA.
    Mayo Clin Proc; 2011 Aug 18; 86(8):762-80. PubMed ID: 21803958
    [Abstract] [Full Text] [Related]

  • 13. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR, Knight M.
    Clin Ther; 2015 Oct 01; 37(10):2153-79. PubMed ID: 26412799
    [Abstract] [Full Text] [Related]

  • 14. Lipid-lowering drug therapy in elderly patients.
    Berthold HK, Gouni-Berthold I.
    Curr Pharm Des; 2011 Oct 01; 17(9):877-93. PubMed ID: 21418034
    [Abstract] [Full Text] [Related]

  • 15. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD.
    Curr Diab Rep; 2019 Nov 21; 19(12):146. PubMed ID: 31754844
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis.
    Zhai C, Hou K, Li R, Hu Y, Zhang J, Zhang Y, Wang L, Zhang R, Cong H.
    J Int Med Res; 2020 Jun 21; 48(6):300060520926349. PubMed ID: 32529863
    [Abstract] [Full Text] [Related]

  • 17. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
    Last AR, Ference JD, Menzel ER.
    Am Fam Physician; 2017 Jan 15; 95(2):78-87. PubMed ID: 28084704
    [Abstract] [Full Text] [Related]

  • 18. Is aggressive lipid-lowering effective and safe in the older adult?
    LaRosa JC.
    Clin Cardiol; 2005 Sep 15; 28(9):404-7. PubMed ID: 16250262
    [Abstract] [Full Text] [Related]

  • 19. Statin intolerance: diagnosis and remedies.
    Pirillo A, Catapano AL.
    Curr Cardiol Rep; 2015 May 15; 17(5):27. PubMed ID: 25894795
    [Abstract] [Full Text] [Related]

  • 20. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.
    Health Technol Assess; 2007 Apr 15; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.